Back to search

University of Southampton

Development of a novel plant expressed conjugate vaccine for HER2-positive breast cancer

Abstract

dc:description.abstract

Overexpression HER2/neu correlates with poor prognosis in many cancers, including breast cancer. HER2-specific monoclonal antibodies including Herceptin® have had significant impact on breast cancer survival rates. However, there are a number of limitations with their use, including tumour recurrence, the requirement for multiple doses and high-cost production. Vaccination, however, can provide long-term tumour specific antibodies and cellular-mediated immune responses. Here the aim was to develop a potent vaccine to target HER2.<br/> <br/>Self-tumour antigen HER2 is poorly immunogenic due to tolerance. Previous studies using DNA vaccines demonstrated that conjugation of tumour antigens to Fragment C of tetanus toxin (FrC) broke tolerance. Here to target HER2 a novel HER2 portion ED44 was generated and conjugated to FrC. The HER2-targeting vaccine subunits were expressed using an efficient plant-based manufacturing process 'magnifection' and were available through collaboration (ICON Genetics, Germany). <br/><br/>Both rat and human versions were generated to study the mechanisms or for clinical application respectively. They were tested in several complementary breast cancer models including non-tolerant (TUBO, D2F2/E2) and tolerant (Balb/neuT) settings. In non-tolerant settings unconjugated ED44 was effective at inducing of protective antibody. In the tolerant model, only ED44-FrC conjugate was effective in inducing high levels of antibody and suppressing already developed tumours. Only ED44-FrC conjugate vaccine induced antibody of high affinity of a wide range of isotypes. FrC-specific T cell help induced by the conjugate vaccine was critical for effective anti-HER2 antibody. <br/><br/>The human ED44-FrC induced sera were able to inhibit HER2-mediated downstream signalling and induced growth inhibition of two HER2positive cell lines. Hence, the novel vaccine is a promising candidate for HER2 positive cancer treatment.<br/><br/>In the last chapter a novel vaccine design that included plant virus particle (PVP) was used to induce anti-HER2 cytotoxic T cells. This sets the foundation for development of this platform in the future.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D.
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Southampton
Year dc:date.issued
2016

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Chotprakaikiat, Warayut
Advisors dc:contributor.advisor
  • Savelyeva, Natalia
  • Ottensmeier, Christian
  • Stevenson, Freda
ORCID person:identifier.orcid

Rights

Language dc:language
English, eng

Chain of custody

source
Harvested from
University of Southampton
Base URL
eprints.soton.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Chotprakaikiat, Warayut. Development of a novel plant expressed conjugate vaccine for HER2-positive breast cancer. doctoral thesis, University of Southampton, 2016.